NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · AMTI · USD
Stock price, earnings
Quote as of Dec 26, 2023, 08:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Applied Molecular Transport Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Applied Molecular Transport Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Applied Molecular Transport Inc. (AMTI), a biopharmaceutical company in the clinical development phase, was founded in 2010 and is based in South San Francisco, California. The firm is dedicated to discovering and advancing a pipeline of oral and respiratory biologic drug candidates, designed to address a variety of medical conditions including autoimmune, inflammatory, and metabolic diseases. Among its investigational treatments, AMT-101 stands out as the lead candidate. This orally administered, gastrointestinal (GI)-selective biologic, derived from rhIL-10, is presently in Phase II clinical trials for the management of ulcerative colitis and other related inflammatory indications. AMTI is also further developing AMT-126, another oral, GI-selective biologic that harnesses interleukin 22. This compound is currently undergoing Phase I clinical studies for the treatment of disorders stemming from impaired intestinal epithelial barrier function. The company's innovative technology platform allows for the creation and development of a broad spectrum of oral biologic therapeutic approaches, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2021 | Feb 24, 2022 | -$0.78-23.81% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$14.20+$0.34 (+2.45%)
Korro Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.74% below the high.
$0.86-$0.02 (-2.73%)
Tvardi Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.83% below the high.
$0.10$0.00 (0.0%)
ObsEva S.A.’s quoted price sits in the lower half of its reported 52-week range, 95.24% below the high.
$0.39+$0.03 (+8.48%)
Apexigen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.35% below the high.
$1.35+$0.09 (+7.14%)
Channel Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 97.51% below the high.
